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CASE REPORT
Endocrine Symptoms as the initial 
Manifestation of Wilson’s disease
Robert Krysiak*, Gabriela Handzlik-Orlik, and Boguslaw Okopien
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia,
Katowice, Poland
Wilson’s disease is a rare genetic disorder of copper metabolism. The difference in copper
tissue accumulation is responsible for the various clinical manifestations of this disorder. If
left untreated, Wilson’s disease progresses to hepatic failure, severe neurological disability,
and even death. Due to the complex clinical picture of Wilson’s disease, its diagnosis relies
on a high index of suspicion. In our paper, we present endocrine symptoms suggesting the
presence of insulinoma and hyperprolactinemia as the initial clinical manifestation of Wil-
son’s disease in a young female. Zinc acetate treatment resulted in the disappearance of hy-
poglycemia, galactorrhea, and menstrual abnormalities.
introduction
Wilson’s disease (hepatolenticular de-
generation) is a rare autosomal recessive in-
herited disorder of copper metabolism. The
mutations in the ATP7B gene lead to im-
paired biliary excretion of copper, the conse-
quence of which is abnormal accumulation
of copper in the liver, basal ganglia, kidneys,
and cornea [1-3]. This results in severe and
potentially life threatening injury to vital or-
gans, especially the liver and nervous system.
Unless  specific  treatment  (with  penicil-
lamine, trientine, or zinc) is given, the dis-
ease  leads  almost  inevitably  to  death. A
characteristic feature of hepatolenticular de-
generation is its variable manifestation, par-
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table 1. Baseline hormonal profile of the patient.
Hormone
Prolactin
GH in the oral glucose tolerance test
IGF-I
ACTH
TSH
FSH**
LH**
Intact parathormone
Free thyroxine
Cortisol 
in the overnight dexamethasone test
in the 250-ﾵg cosyntropin test
Urine free cortisol
DHEA-sulphate 
17ʲ-oestradiol**
Testosterone
Androstendione
17-hydroxyprogesterone** 
Free androgen index
Insulin
Baseline
after the fasting test
C-peptide
Baseline
after the fasting test
Proinsulin after the fasting test
ʲ-hydroxybutyrate after the fasting test
unit
ﾵg/L
ﾵg/L
ﾵg/L
ng/L
mU/L
U/L
U/L
ng/L
pmol/L
ﾵg/dL
ﾵg/day
ﾵg/dL
ng/L
ﾵg/L
ﾵg/L
ﾵg/L
%
mU/L
ﾵg/L
pmol/L
mmol/L
concentration
12.7*
0.2
137.0
48.2
1.95
6.82
6.84
42.2
16.5
1.2
27.2
62.2*
281.5
60.5
0.35
1.7
0.45
4.2
18.6
0.0
1.5
0.0
0.1
3.5
normal limits
5.0-25.0
<1.0
72.0-335.0
20.0-60.0
0.4-4.5
3.4-12.5
2.3-12.7
10.0-70.0
12.0-22.0
<1.8
>19.6
20.0-90.0
80.0-450.0
30.0-100.0
0.15-0.8
0.6-3.2
0.2-1.0
<5.0
6.0-25.0
<3.0
0.6-2.0
<0.6
<5.0
>2.7
*Mean value of several measurements
**Early follicular phasetially dependent on the age of the disease
onset that makes it legitimate to consider Wil-
son’s disease in the differential diagnosis of
various pathologies [1,2]. Retrospective data
show that its earliest manifestation is in 42
percent of cases of liver damage, in 34 percent
of neurological disorders, in 12 percent of
hematologic disorders, in 10 percent of psy-
chiatric symptoms, while in 1 percent of kid-
ney dysfunction [3].
Here  we  report  a  case  of  a  young
woman with Wilson’s disease who initially
presented with symptoms suggestive of ex-
cessive prolactin and insulin release. We
present diagnostic and treatment dilemmas
associated with Wilson’s disease in this case
patient.
caSE prESEntation
A 24-year-old woman was admitted to
our hospital to establish the causes of galact-
orrhea, menstrual abnormalities, and hypo-
glycemia. Nipple discharge in response to
breast manipulation appeared for the first time
at the age of 19. Approximately at the same
time, the patient began to complain of men-
strual  abnormalities,  first  beginning  with
oligomenorrhea, which advanced to amenor-
rhea.  High  doses  (up  to  15  mg/day)  of
bromocriptine treatment prescribed by a gy-
necologist resulted in only partial improve-
ment (galactorrhea reduction, oligomenorrhea
instead of amenorrhea). Taking into consider-
ation moderate effectiveness of the therapy
and poor drug tolerance (nausea, vomiting,
and orthostatic hypotension), the bromocrip-
tine treatment was replaced with oral contra-
ceptives. After discontinuation of a 14-month
treatment with contraceptives, eumenorrhea
recurred with the reappearance of amenor-
rhea. Looking further back in the patient his-
tory revealed that at the age of 23, the patient
started  to  experience  symptoms  of  hypo-
glycemia (sweating, pallor, hand tremor, and
palpitation attacks), confirmed several times
by ambulatory glucose measurement. These
symptoms  occurred  predominantly  in  the
morning, late afternoon, and during physical
exertion. The symptoms gradually increased
in frequency and intensity but subsided after
candies or sweet drink consumption. Addi-
tionally, vision impairment, convulsions, and
transient motor defects appeared on several
occasions. Because of clinical features sug-
gesting  hyperprolactinemia,  we  assayed
plasma prolactin levels repeatedly, each time
obtaining results within normal limits (Table
1). On further examination, the characteristics
of the breast discharge were neither inflam-
matory nor neoplastic. However, the magnetic
resonance imaging (MRI†) of the pituitary
gland revealed a small, hypointense area (3.5
mm in diameter) that could be a microade-
noma. Pituitary tests showed no hormonal ac-
tivity of this lesion (Table 1). Transvaginal
ultrasonography (USG) examination revealed
features  of  polycystic  ovary  syndrome
(PCOS) not accompanied by any abnormali-
ties in gonadal and adrenal androgen secre-
tion.
Hypoglycemia suggested the presence of
insulinoma. The fasting test, the gold standard
in diagnostics for this tumor type, had to be
stopped after 36 hours because of sudden pre-
syncope with neuroglycopenia and the fea-
tures  of  enhanced  sympathetic  tone.
However, the result of the test excluded the
insulinoma diagnosis because in conditions
of low glycemia (42 mg/dL), serum levels of
insulin, C-peptide, and proinsulin were unde-
tectable and concentration of ʲ-hydroxybu-
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Figure 1. Copper deposits in the posterior
limiting lamina (Descemet’s membrane) of
the cornea (Kayser-Fleischer ring).tyric acid was not decreased. Simultaneously
performed biochemical diagnostics suggested
Wilson’s disease: decreased levels of cerulo-
plasmin (140 mg/L, normal values: 200-600),
an increased concentration of free copper (17
ﾵg/dL, normal values: less than 10), an in-
creased 24-hour urine copper excretion (131
ﾵg/24h, normal values <80), the presence of
Kayser-Fleischer ring in the cornea (Figure
1), and an abnormal signal from basal gan-
glia (Figure 2). The ultrasound and MRI im-
ages  of  the  liver  were  normal.  Doppler
ultrasound revealed only discrete features of
portal  hypertension  without  esophageal
varices in endoscopic examination. Wilson’s
disease was confirmed by liver biopsy (Fig-
ure 3), increased hepatic copper (320 ﾵg/g
dry weight), and identification of H1069Q
mutation in the gene ATP7B. Because of the
Wilson’s disease diagnosis, d-penicillamine
was administered, which was later replaced
(due to thrombocytopenia) with zinc acetate
(150 mg/day in three divided doses).
Hypoglycemic  symptoms  occurred
twice at the initiation of the treatment,
but subsided after 2 months of continu-
ous therapy. After 4 months of treat-
ment,  menstruation  returned  while
galactorrhea disappeared. Control MRI
of pituitary gland did not reveal any ab-
normalities. 
diScuSSion
The  presented  above  case  of  a
young woman indicates that there is a
possibility of the initial endocrine man-
ifestation of Wilson’s disease, suggesting the
coexistence of prolactinoma and insulinoma.
Although Wilson’s disease has been evi-
denced to cause the development of hypo-
glycemia [2], galactorrhea, and abnormal
menstruation [4], these disturbances mani-
fested in the advanced stages of the disease
and were accompanied by the clinical pic-
ture of overt hepatolenticular degeneration
[2]. Hypoglycemia usually developed as a
result of cirrhosis-induced hepatic failure.
On the other hand, menstrual abnormalities
(except one case) [5] were secondary to hy-
poestrogenism induced by a reduction in
ovarian aromatase activity, and therefore
they were not accompanied by galactorrhea
[4]. Interestingly, the lack of a typical clini-
cal presentation of Wilson’s disease, a nor-
mal morphological picture of the liver on
USG and MRI, and only discrete features of
portal hypertension (a poorly developed col-
lateral  circulation  without  esophageal
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Figure 2. Hyper-
intensity of the
caudate nuclei on
magnetic reso-
nance imaging
(spin-echo T1 se-
quence).
Figure 3. Core needle biopsy of the liver. Orcein
staining revealed hepatic copper accumulation.varices in endoscopic examination) indicate
that the observed symptoms in our patient
appeared at the initial stages of the disease.
Nevertheless, Kayser-Fleischer corneal ring,
low  plasma  levels  of  ceruloplasmin,  in-
creased plasma levels of free copper, and an
increased urine excretion of this element
show that even in the initial stage, establish-
ing the correct diagnosis is possible.
Time parallelism between the regres-
sion of hypoglycemia, galactorrhea, men-
strual  abnormalities,  and  the  eventual
improvement in the clinical state not only
strongly suggests the relationship between
clinical picture of the patient and Wilson’s
disease, but also excludes that the presented
symptoms resulted from concomitant disor-
ders. Efficacy of zinc preparations, which
through  metallothionein  enhance  copper
binding and thereby inhibit copper absorp-
tion in enterocytes [1], also indicates that en-
docrine  symptoms  may  be  reversible  if
therapy is introduced early. 
Galactorrhea and menstrual abnormali-
ties in connection with the presence of a hy-
pointense lesion in the pituitary suggested
prolactinoma. However, normal plasma pro-
lactin concentration excluded this diagnosis.
Furthermore,  normal  plasma  levels  of
growth hormone (GH), ACTH, FSH, LH,
and TSH contradicted any other hormonal
activity of the microadenoma. No abnor-
malities in the pituitary gland on the control
MRI, performed after 6 months of therapy
with zinc acetate, indicate that the pituitary
lesion present in the onset probably corre-
sponded  to  local  copper  accumulation,
which receded as a result of treatment. The
above-mentioned explanation is in agree-
ment with observations of other authors [6],
who found an abnormal response of lac-
totropes to gonadoliberin due to copper de-
posits in the pituitary gland of male patients
with Wilson’s disease.
A very similar clinical picture of our pa-
tient to this observed in hyperprolactinemia
may suggest an increased susceptibility of
glandular tissue to prolactin, due to elevated
copper accumulation in mammary gland.
Several facts indirectly confirm this inter-
pretation. To begin, zinc acetate caused the
clinical improvement of patient state, al-
though there was no clear influence of this
form of therapy on prolactin concentration.
Subsequently, although bromocriptine did
not bring satisfactory effects, it caused lim-
ited clinical improvement. These findings
may  explain  the  abnormal  prolactin-pro-
lactin receptor interaction in peripheral tis-
sues.  Finally,  prolactin  enhances  copper
transport in glandular cells of the breast,
which strongly suggests the existence of the
interaction between copper and prolactin in
the mammary gland [7]. It is possible that
increased accumulation of copper in mam-
mary tissues strengthens the local action of
prolactin in this gland. Interestingly, if sim-
ilar hypersensitivity occurs in the gonads, it
may explain ultrasound picture of PCOS,
despite normal secretion of androgens and
gonadotropins. 
In our patient, we observed Whipple’s
triad: 1) clinical symptoms of neuroglycope-
nia and catecholamine excess induced by
fasting or exertion; 2) low glucose levels
(<45 mg/dL) associated with clinical signs of
hypoglycemia; and 3) reversal of symptoms
after meal consumption [8]. The only differ-
ences compared to the clinical picture of in-
sulinoma  were  the  age  of  the  patient
(insulinoma usually manifests between 40
and 60 years of age) and the lack of weight
gain, observed in fewer than 30 percent of
patients with insulinoma. Thus, the case pre-
sented herein indicates that Whipple’s triad
cannot be treated as patognomic for insuli-
noma, and if no pathological changes in the
pancreas are observed, it requires further di-
agnostics toward hepatolenticular degenera-
tion. We presume that hypoglycemia resulted
from hepatic dysfunction, caused by copper
deposits in the liver that disturbed glucose
metabolism regulation in this structure.
concluSionS
The presented above atypical course of
Wilson’s  disease  confirms  its  complex
symptomatology and evidences that hypo-
glycemia and galactorrhea of undefined eti-
ology  may  indicate  hepatolenticular
degeneration.  Furthermore,  it  should  be
253 Krysiak et al.: Endocrine symptoms and Wilson’s diseasetaken into account even when typical clini-
cal symptoms of this disease are absent,
whereas image and hormonal examination
are within normal range.
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